CJC-1295
Extended-Release GHRH Analogue
Molecular Data
- Formula
- C152H252N44O42
- Molecular Weight
- 3367.97 g/mol
01
Overview
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) that has been modified to extend its half-life dramatically — from minutes to days. Available in two forms: with Drug Affinity Complex (DAC) for weekly dosing and without DAC (MOD GRF 1-29) for pulsatile administration. It drives increases in GH and IGF-1 over sustained periods.
02
Mechanism of Action
CJC-1295 binds to GHRH receptors on somatotroph cells in the pituitary gland, stimulating GH synthesis and release. The DAC modification attaches to plasma albumin via maleimide chemistry, extending its duration of action to 6-8 days. This maintains elevated GH/IGF-1 levels without mimicking the physiological pulsatile pattern.
03
Research Highlights
Phase II trials demonstrate dose-dependent increases in GH and IGF-1 lasting up to 2 weeks
Body composition studies show favorable changes in lean mass and fat mass ratio
Safety research shows minimal pituitary desensitization compared to continuous GH administration
04
Dosage
Administration & Timing
Subcutaneous (SC) injection into abdominal or gluteal subcutaneous tissue, once or twice daily. Research protocols typically administer before sleep to align with natural GH pulsatility.
Dosage Guidelines
Cycle Length
4–12 weeks; longer protocols monitor IGF-1 levels.
05
Reconstitution
Solvent
Bacteriostatic Water (0.9% benzyl alcohol)
Volume
2 mL added to a 2 mg vial
Concentration
1 mg/mL (1,000 mcg/mL)
Storage
Refrigerate at 2–8 °C; protect from light. Discard 30 days after reconstitution.
Notes
CJC-1295 with DAC has an ~8-day half-life; without DAC, ~30 minutes. Adjust dosing frequency accordingly. Avoid combining with somatostatin-active compounds.
Research Reference Only
Dosage and reconstitution values reflect commonly cited ranges from published research literature and are presented for educational and research reference only. This is not medical advice or a dosing recommendation. HEXAGEN does not endorse human use of any compound. Always consult a qualified healthcare professional.
Research Disclaimer
CJC-1295 is for educational and research purposes only. Not intended as medical advice. Consult a qualified healthcare professional before making any health-related decisions.
Related Compounds
View All
CJC-1295 Knowledge Graph
Explore how CJC-1295 connects to mechanisms, research goals, related compounds, research stacks, and scientific references. Drag nodes, zoom, and filter by type.
No nodes match the active filters.
CJC-1295 — Common Research Questions
What is CJC-1295?
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) that has been modified to extend its half-life dramatically — from minutes to days. Available in two forms: with Drug Affini... CJC-1295 belongs to the Weight Loss research category and is studied for its extended-release ghrh analogue.
How does CJC-1295 work?
CJC-1295 binds to GHRH receptors on somatotroph cells in the pituitary gland, stimulating GH synthesis and release. The DAC modification attaches to plasma albumin via maleimide chemistry, extending its duration of action to 6-8 days. This maintains elevated GH/IGF-1 levels without mimicking the physiological pulsatile pattern.
What are the key research benefits of CJC-1295?
Sustained growth hormone pulse amplitude amplification. IGF-1 elevation supporting body composition. Enhanced fat mobilization and lean muscle support. Improved sleep quality and recovery. Long half-life enabling infrequent dosing (with DAC). Synergistic effect when combined with GHRPs.
What is the molecular structure of CJC-1295?
CJC-1295 has the molecular formula C152H252N44O42 and a molecular weight of 3367.97 g/mol. This structural information is important for researchers studying receptor binding and pharmacokinetics.
What does the research say about CJC-1295?
Phase II trials demonstrate dose-dependent increases in GH and IGF-1 lasting up to 2 weeks Body composition studies show favorable changes in lean mass and fat mass ratio Safety research shows minimal pituitary desensitization compared to continuous GH administration These findings are based on preclinical and clinical research. CJC-1295 is a research compound and these studies do not constitute medical advice.
Is CJC-1295 FDA approved?
No. CJC-1295 is not FDA-approved for any indication. It is a research chemical studied in preclinical and early clinical research. These compounds are not approved for human therapeutic use and should only be studied in appropriate research settings.
What category does CJC-1295 belong to?
CJC-1295 belongs to the Weight Loss category, which focuses on compounds studied for their roles in metabolic regulation, growth hormone signaling, and targeted adipose tissue reduction. You can explore more compounds in this category on the Weight Loss pillar page.
Related Articles
Tesamorelin: Clinical Data for Visceral Fat Reduction
Phase III trial data showing 15-18% visceral fat reduction and the FDA approval rationale for Egrifta®.
AOD-9604: Lipolysis Without Growth Effects
How AOD-9604's C-terminus fragment of HGH stimulates lipolysis without the growth-promoting effects of full-length HGH.
CJC-1295 + Ipamorelin: Synergistic GH Secretagogue Research
Examining the complementary mechanisms of CJC-1295 (GHRH analogue) and Ipamorelin (ghrelin mimetic) in research settings.
Scientific References
Teichman et al. — "CJC-1295: long-acting GHRH analogue" (J Clin Endocrinol Metab, 2006)
Iyengar et al. — Phase II body composition data, Endocrine Soc, 2007
Phase II trials demonstrate dose-dependent increases in GH and IGF-1 lasting up to 2 weeks
Body composition studies show favorable changes in lean mass and fat mass ratio
Safety research shows minimal pituitary desensitization compared to continuous GH administration